NASDAQ:PALI Palisade Bio Q1 2026 Earnings Report $2.09 -0.03 (-1.42%) Closing price 08/6/2026 04:00 PM EasternExtended Trading$2.10 +0.01 (+0.48%) As of 08/6/2026 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Palisade Bio EPS ResultsActual EPS-$0.05Consensus EPS -$0.04Beat/MissMissed by -$0.01One Year Ago EPSN/APalisade Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APalisade Bio Announcement DetailsQuarterQ1 2026Date5/12/2026TimeAfter Market ClosesConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsPalisade Bio's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Palisade Bio Earnings HeadlinesPalisade Bio jumps following Oppenheimer outperform initiationJuly 23, 2026 | msn.comPalisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10, 2026 | markets.businessinsider.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Palisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10, 2026 | globenewswire.comPalisade Bio: A Unique MoA Targeting The UC And Crohn's Disease MarketsJuly 10, 2026 | seekingalpha.comPALI stock heads for best day in seven months – what’s driving today’s rally?June 29, 2026 | msn.comSee More Palisade Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email. Email Address About Palisade BioPalisade Bio (NASDAQ:PALI) is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations. Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events. View Palisade Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boeing's Comeback Is Building Momentum—Is It Real?Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is FallingBed Bath & Beyond Renovates: The Neighborhood BlueprintSpaceX: Love the Company, But the Stock Is a Harder CallDisney Sets Up for a Magical Year in 2027Astera Labs' Post-Earnings Pullback May Be Last Chance to Buy Below $360Why Analysts Are Bullish on a Stock That's Down 20% Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Nebius Group (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
